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Context: Perturbations in thyroid function are common in older individuals but their significance
in the very old is not fully understood.
Objective:This study sought todeterminewhether thyroidhormonestatusandvariationof thyroid
hormones within the reference range correlated with mortality and disability in a cohort of
85-year-olds.
Design: A cohort of 85-year-old individuals were assessed in their own homes (community or
institutional care) for health status and thyroid function, and followed formortality and disability
for up to 9 years.
Setting and Participants: Six hundred and forty-three 85-year-olds registered with participating
general practices in Newcastle and North Tyneside, United Kingdom.
Main Outcomes: All-cause mortality, cardiovascular mortality, and disability according to thyroid
disease status and baseline thyroid hormone parameters (serum TSH, FT4, FT3, and rT3). Models
were adjusted for age, sex, education, body mass index, smoking, and disease count.
Results: After adjustment for age and sex, all-cause mortality was associated with baseline serum
rT3 and FT3 (both P  .001), but not FT4 or TSH. After additional adjustment for potential con-
founders, only rT3 remained significantly associated with mortality (P .001). Baseline serum TSH
and rT3 predicted future disability trajectories in men and women, respectively.
Conclusions:Our study is reassuring that individuals age 85 ywith both subclinical hypothyroidism
and subclinical hyperthyroidism do not have a significantly worse survival over 9 years than their
euthyroidpeers.However, thyroid function testsdidpredictdisability,withhigher serumTSH levels
predicting better outcomes. These data strengthen the argument for routine use of age-specific
thyroid function reference ranges. (J Clin Endocrinol Metab 101: 4385–4394, 2016)
Although overt thyroid dysfunction has long been as-sociated with cardiovascular disease, the effects of
subtle variations in thyroid function are less clear (1–3).
However, this topic has taken on increasing significance,
given that it has been recognized that up to 3% of older
individuals have a serumTSH concentration that is below
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the healthy reference interval for younger people (subclin-
ical hyperthyroidism), and approximately 10% have an
elevated serum TSH level (subclinical hypothyroidism)
(4–7). The high prevalence of these mild or subclinical
abnormalities of serumTSHwith advancing age has led to
a significant body of research concerning the possibility
that these changes may presage ill health (2, 8–10). Sim-
ilarly, the possibility that variations of serum TSH and
circulating thyroid hormones even within the healthy ref-
erence rangemay predict current or future disease has also
been examined (3, 11).
Twenty years ago, a low serum TSH level was first
associated with an increased risk of atrial fibrillation (AF)
(12), and this association has been reproducedmany times
since (13–16). Similarly, longitudinal studies have shown
that a low serum TSH concentration is associated with a
higher rate of cardiovascular events, osteoporotic frac-
ture, dementia, and death (14, 17–20). However, there is
significant heterogeneity within the literature, with some
largeandwell-conducted studies failing to reproduce these
associations (13, 21), as well as unresolved questions
about causality. Similarly, several studies have found an
association of elevated serum TSH with adverse cardiac
outcomes, including myocardial infarction (MI), heart
failure, and mortality (8, 10, 21–24). Nevertheless, these
findings have not been reproduced by all studies (13, 17,
25, 26), suggesting that there may be heterogeneity be-
tween the populations studied, or confounding by comor-
bidities,medications,methodologyorotherunknown fac-
tors. Some authors have suggested that an elevated serum
TSH inolder agemight havenoadverse effect onhealth (7,
27, 28) although one study of individuals age 85 years
showed that a high serum TSH at baseline was associated
with a favorable outcome compared with that of euthy-
roid contemporaries (29). However, data from subjects in
advanced old age is scarce and this finding has not been
confirmed (2). Thus, mild biochemical abnormalities of
thyroid function are commonwith increasing age but their
significance remains unclear, particularly in the very old.
In this study we examined the relationship between thy-
roid function and subsequent outcome in a cohort of 85-
year-old individuals.
Participants and Methods
Participants and study design
Studyparticipantsweremembersof theNewcastle 85
Study, a longitudinal study of health trajectories and out-
comes in a single-year birth cohort (1921) recruited at age
85 years from general (family) practices in Newcastle and
North Tyneside, which is described in detail elsewhere
(30, 31). The recruited cohort was sociodemographically
representative of the general United Kingdom population
and included institutionalized older adults (31). At study
baseline (2006/07), comprehensive measures of health
were collectedacrossmultiple clinical, biological, andpsy-
chosocial domains. A health assessment—comprising
questionnaires, anthropometric measurements, physical
and cognitive function tests, and a fasting blood sample—
was carried out in the participant’s usual residence by a
researchnurse.General practicemedical recordswere also
reviewed to extract data on diagnosed diseases and pre-
scribedmedication. In participants whowere temporarily
hospitalized at the time of recruitment, assessments were
undertaken after discharge. All participants provided
written informed consent except for those who lacked ca-
pacity to consent (for example, in dementia). For the latter
group, an opinion was obtained from a close relative or
carer, as requiredbyUK law (32).The studywas approved
by the Newcastle and North Tyneside 1 Research Ethics
Committee (Ref: 06/Q0905/2).
Health assessment, disease counts, and disability
The prevalence of common diseases was determined by
evaluation of general practitioner records and/or health
assessments. Diseases were scored as either present or ab-
sent for 17 selected chronic diseases and a disease count
calculated as detailed previously (33). Briefly, these were:
hypertension, ischemic heart disease, cerebrovascular dis-
ease, peripheral vascular disease, heart failure, atrial flut-
ter or fibrillation, arthritis (osteoarthritis or rheumatoid
arthritis), osteoporosis, chronic obstructive pulmonary
disease or asthma, other respiratory disease, diabetes mel-
litus (type 1 or 2), cancer (diagnosed within the previous
five years), eye disease, dementia, Parkinson’s disease,
anemia, and renal impairment (estimated glomerular fil-
tration rate  30 mL/min/1.73m2) [methodology as re-
ported in Collerton et al (31) but omitting thyroid disease
from the disease count]. A disability score was created
from17 activities of daily living at baseline, 18months, 36
months, and 60 months, and, using group-based trajec-
torymodeling that accounted formortality, four disability
trajectorieswere identified formen andwomen separately
(33). Information on date and cause of death (to ICD-10)
were provided from linkage with the national registration
system.
Blood samples and biochemical analysis
After an overnight fast, 40 mL blood was drawn from
the antecubital vein between 0700 and 1030 hours. Blood
sampling tookplace between June 2006 andAugust 2007.
Measurement of TSH, FT4, and FT3 was performed using
a Centaur platform (Seimens). Intra-assay coefficients of
variation were serum TSH, 3.8% (at 5.3 mU/L); FT4,
7.9% (at 13.5 pmol/L) and FT3, 3.1% (at 10.5 pmol/L).
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Serum reverse T3 (rT3) was assayed in duplicate by RIA,
using antiserum 3684 at a final dilution of 1:600 000 and
sample volumes of 25 L, as described (34). Thyroid per-
oxidase antibodies were assayed by Advia chemilumines-
cent assay on the Centaur platform with an intra-assay
coefficient of variation of 17.7% at a concentration of
87.2 U/L. The following reference ranges were used: TSH,
0.4–4.0 mU/L; FT4, 11.0–23.0 pmol/L; FT3, 3.5–6.5
pmol/L; TPO antibodies, 0–60 U/L. Overt hypothyroid-
ism was defined as TSH at least 10.00 mU/L or TSH,
4.01–9.99 mU/L and FT4  10.9 pmol/L; subclinical hy-
pothyroidism was TSH, 4.01–9.99 mU/L and FT4 at least
11.0 pmol/L; euthyroid was TSH, 0.40–4.00 mU/L and
FT4, 11.0–23.0 pmol/L; subclinical hyperthyroidism
TSH 0.399 mU/l, FT4 23.1, FT3 6.6; overt hyper-
thyroidismTSH 0.099 and either FT4 23.0 pmol/L or
FT3 at least 6.6 pmol/L.None of the participants classified
as euthyroid from biochemical analysis had thyroid dis-
ease recorded in the general practice records.
Both health assessment and general practice records data
were available for 845 participants at study baseline, of
whom760 had complete data on serumTSH, FT3, FT4, and
rT3. An additional 116 were excluded as they were on thy-
roidmedicationormedication interferingwith thyroid func-
tion (levothyroxine, antithyroiddrugs, amiodarone, lithium,
corticosteroids). One additional participant was excluded
because she was diagnosed with hypopituitarism as part of
the study assessments, leaving 643 participants whose mor-
tality outcome was documented until January 1, 2015.
Statistical analysis
Differences in the baseline characteristics between the
groups defined by biochemical status were assessed by 2
tests for the binary variables and Kruskal-Wallis for or-
dinal and continuous variables (none of which were nor-
mally distributed). The time interval for survival was cal-
culated as that between time of blood draw and time of
death or January 1, 2015. Kaplan-Meier plots were used
to assess the relative risk of mortality by biochemical sta-
tus separately by sex. Cox proportional hazards models
were employed to explore the relative risk of mortality
associated with each of the four serum thyroid measures
separately (TSH, FT4, FT3, rT3) as continuous variables
and for estimating hazard ratios (HRs) and 95% confi-
dence intervals (CIs) adjusted first, for age and sex (Model
1), and then for potential confounders: education (0–9 y,
10–11 y, 12 y), bodymass index (BMI), smoking (none,
ex, current) and disease count (Model 2). Separatemodels
were fitted to the entire and the euthyroid cohorts for
all-cause mortality and cardiovascular mortality (ICD-10
codes I00-I99). The proportional hazards assumptionwas
tested by examining the Schoenfeld residuals. Potential
nonlinear relationships between each of the thyroid mea-
sures and all-cause and cardiovascular mortality were ex-
aminedby fitting restricted cubic splines (35).The effect of
the thyroid parameters on disability was examined by fit-
ting ordinal logistic regression models adjusted for the
potential confounders listed earlier. Analyses were under-
taken in SAS version 9.4 (SAS Institute).
Sensitivity analyses
To compare our results more directly with the Leiden
birth cohort of the same age (29), we repeated the Cox
proportional hazards regression modeling adjusting for
the samebaseline covariates (age, sex, albumin,C-reactive
protein [CRP], disease count, mini mental state examina-
tion [MMSE] score, disability score, subjective health).
During the first 5 years of the follow-up period, 21
participants were newly treated with levothyroxine and a
further participant with antithyroid drugs. We repeated
survival analyses excluding these 22 but the results re-
mained the same (data not shown).
Results
Mortality by thyroid status
In this population of 643 85-year-olds, 83.1% (n 
534) were euthyroid at baseline, 12.5% (n 79) had sub-
clinical hypothyroidism, 2.9% (n  19) had subclinical
hyperthyroidism, and less than 1%were overtly hypothy-
roid (0.9%, n 6) or hyperthyroid (0.8%, n 5) (Table
1). Table 1 also shows the baseline characteristics for all
participants (n  643) and separately for those classified
as euthyroid (n  534). At baseline, biochemical thyroid
status (including euthyroid, subclinical, and overt hypo-
and hyper-thyroidism) was associated with years in edu-
cation (2 10.86; df 4; P .028), medical history of
ischemic heart disease (29.27; df2;P .001), serum
albumin (F 4.33; df 2;P .014), CRP (F 5.06; df
2; P  .007) and disability score (2  7.29; df  2; P 
.03) (Supplemental Table 1).
Owing to the small number of overt hyper- and hypo-
thyroid subjects, we combined the subclinical and overt
biochemical categories for plotting the Kaplan-Meier
curve for all-cause and cardiovascular mortality (Figure
1). No significant difference was found between the cat-
egories for all-cause mortality (male: P .32; female: P
.54) or cardiovascular mortality (male: P  .94; female:
P .18). Nor was association found between thyroid sta-
tus and either all-cause mortality or cardiovascular mor-
tality after adjustment for age and sex, or after further
adjustment for potential confounding factors (Supple-
mental Table 2).
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Individual serum thyroid parameters
Analysis of each of the serum thyroid hormones indi-
vidually showed that all-cause mortality was negatively
associated with FT3 concentrations (HR 0.81; 95%CI,
0.73–0.91;P .001) and positively associatedwith levels
of rT3 (HR  1.23; 95% CI, 1.12–1.34; P  .001) al-
though only rT3 remained significantly associated after
adjustment for the potential confounding baseline factors
of education, BMI, smoking status, and disease count (Ta-
ble 2). Similar trends were found for cardiovascular mor-
tality although, due to smaller number of deaths, the as-
sociation of rT3 with cardiovascular mortality was no
longer significant after adjustment for baseline factors
(Table 2). When analyses were repeated for the subset of
euthyroid participants (n  534), the same associations
were found although all-cause mortality associations for
both FT3 and rT3 remained significant after adjustment
for baseline factors (Table 2).
Test of the proportional hazards assumptions showed
that none of the variables violated the assumptions. Anal-
ysis of the individual thyroid hormones by restricted cubic
splines to check for nonlinear associations with all-cause
and cardiovascular mortality in the entire cohort showed
that only FT3 had a nonlinear association with mortality,
after adjustment for potential confounders, suggesting
that both low and high FT3 ( 6.75 pmol/L) values were
associatedwith increasedall-causemortality (Figure2and
Supplemental Figure 1).
To examine whether our results were dependent upon
the choice of confounders, we repeated analyses using the
same confounding factors as Gussekloo et al (29), (age,
sex, albumin, CRP, disease count,MMSE score, disability
score, subjective health) and restricting survival to 4 years.
Results were unchanged with only rT3 showing a signifi-
cant relationship with mortality.
Disability
We examined the relationship between each of the thy-
roid functionmeasures (TSH,FT3, FT4, rT3) anddisability
trajectory during the first 60months of the study, for men
and women separately (Table 3). The distributions of the
thyroid hormones for each disability trajectory are shown
in Supplemental Table 3. For women there was a signifi-
cant trend toward increasing disability with decreasing
Table 1. Baseline Characteristics of Study Sample
Characteristic Total (n  643) Euthyroid (n  534)
Age, y, mean (SD) 85.5 (0.4) 85.5 (0.4)
Male, % (n) 42.0 (270) 43.6 (233)
BMI, mean (SD) 24.4 (4.4) 24.5 (4.5)
Current smoker, % (n) 5.6 (36) 5.3 (28)
Basic education, % (n) 63.6 (404) 64.2 (339)
Living in care home, % (n) 8.7 (56) 8.6 (46)
Medical history, % (n)
Diabetes 14.1 (91) 14.2 (76)
Hypertension 58.2 (374) 59.0 (315)
IHD 34.4 (221) 37.3 (196)
Stroke 13.8 (89) 13.7 (73)
Cancer 6.4 (41) 6.2 (33)
Disease count, median (IQR) 4 (3–6) 4 (3–6)
Disability score, median (IQR) 3 (1–7) 3 (1–7)
MMSE score, median (IQR) 28 (25–29) 28 (25–29)
Fair or poor self-rated health, % (n) 19.9 (120) 20.9 (110)
Survival time, mo, median (IQR) 65.6 (32.6–92.6) 64.6 (32.4–91.1)
Deaths, % (n) 68.4 (440) 70.2 (375)
Cardiovascular deaths, % (n) 39.2 (252) 40.6 (217)
TSHa, mU/L 1.87 (0.27–6.53) 1.73 (0.58–3.80)
FT3
a, pmol/L 4.54 (3.60–5.5) 4.52 (3.60–5.40)
FT4
a, pmol/L 15.20 (11.0–21.0) 15.24 (11.0–20.0)
rT3
a, nmol/L 0.40 (0.25–0.67) 0.40 (0.26–0.67)
TPOAbs positive, % (n) 15.9 (102) 12.6 (67)
Albumina, g/L 40.03 (33.00–46.00) 40.03 (33.00–46.00)
C reactive proteina, mg/L 2.65 (0.30–52.20) 2.67 (0.30–52.20)
Overt hypothyroid 0.9 (6) —
Subclinical hypothyroid 12.3 (79) —
Euthyroid 83.1 (534) 534 (100)
Subclinical hyperthyroid 2.9 (19) —
Overt hyperthyroid 0.8 (5) —
Abbreviations: IHD, ischemic heart disease; IQR, interquartile range; TPOAbs, thyroid peroxidase antibodies.
a Geometric mean, 2.5–97.5th percentiles
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levels of TSH, FT3, and increasing levels of rT3, although
after adjustment for potential confounders only rT3 re-
mained significantly associated with increased disability
(Table 3). Trends for men were in a similar direction to
women although after adjustment, only decreasing levels
ofTSHwerepredictiveof increaseddisability. FT4wasnot
associated with disability trajectory for either men or
women.
Discussion
Mortality
The significance of mild disturbances of thyroid func-
tion in older individuals is poorly understood, particularly
in the very old. The most frequent abnormality found is a
raised serum TSH with circulating thyroid hormone con-
centrations that are within reference range, correlating
with the state of subclinical hypothyroidism, and some
studies suggest an adverse effect of this state (8, 10, 22, 24)
whereas others show a neutral or even protective effect on
outcome (2, 17, 25, 29, 36, 37). Notably, the Leiden 85
study, a cohort study of 85-year-olds with a similar design
to our study, found that subclinical hypothyroidism was
associated with reduced all-cause mortality and cardio-
vascular mortality (29). This finding, along with the re-
sults of familial studies of the oldest old (7, 38), suggests
that an elevated serum TSH may be positively associated
with longevity and favorable outcomes in the very old.
This led us and others to suggest that there may be age-
related differences in the vascular risk associated with a
raised serum TSH, with higher risks found in younger
individuals that attenuated with advancing age (27, 39,
40). In the current study we have examined a substantial
cohort of 85-year-olds and followed their outcome for up
to 9 years. We find that baseline serum TSH had no sub-
stantial association with all-cause or vascular mortality in
our cohort, which confirms the findings of many previous
studies (2, 13, 17, 25, 29, 36), albeit in a cohort of older
participants. These findings, therefore, provide further re-
assurance that subclinical hypothyroidism is a benign
state in advanced older age (2, 29). Furthermore, we also
show that variation of serum TSH within the reference
interval is not associated with impaired survival. Indeed,
perhaps parallel to the findings of the Leiden 85study
(29), when only euthyroid participants were considered
there is a hint of a protective effect of higher serum TSH
on all-cause mortality, although this did not persist after
adjustment for comorbidities. In addition, lower serum
TSH was associated with disability in men, with a non-
significant though similar trend in women.Whether there
Figure 1. Cumulative survival (all deaths and cardiovascular deaths) of participants based on thyroid status, by sex.
doi: 10.1210/jc.2016-1935 press.endocrine.org/journal/jcem 4389
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 24 November 2016. at 00:35 For personal use only. No other uses without permission. . All rights reserved.
could be a survival benefit associated with subclinical hy-
pothyroidism at this age remains an open question, and
our study does not exclude this possibility. However, sen-
sitivity analysis in our cohort, using exactly the same ad-
justment factors as the Leiden 85 study failed to repro-
duce this finding in participants of the same age, albeit in
a later birth cohort.
In contrast with subclinical hypothyroidism, many pre-
vious studies have shown that low serum TSH is associated
with poor outcomes, either increased all-cause or vascular
mortality, or AF (12–14, 17, 29, 36, 37). This has led to
suggestions that patients with low TSH should be aggres-
sively treated for hyperthyroidism to avoid these complica-
tions despite a complete lack of compelling (level 1) evidence
to support the effectiveness of this strategy (1, 41, 42). Al-
though this current study does not support an increase in
mortality associatedwith lowTSH, there are a relatively low
number of participants with subclinical or overt hyperthy-
roidism in this study (24 in total), so this result is less robust
than that for individuals with higher serum TSH concentra-
tions or subclinical hypothyroidism. Nevertheless, the find-
ing of no adverse effect associated with lower serum TSH
concentration within the reference range is consistent with
several other studies, and broadly reassuring.
Serum T4 is metabolized either to the active thyroid
hormone T3 or to the inactive rT3 in a reciprocal manner
depending upon the relative actions of the tissue deiodi-
nase enzymes (deiodinase types 1 to 3). Reduced circulat-
ing concentration of free T3 is a sensitive marker of ill
health (43). Indeed, fasting, cold exposure, and even mi-
nor infective or inflammatory disease are sufficient to re-
duce serum FT3 and elevate rT3 in otherwise-healthy in-
dividuals (44, 45). In our analysis, higher serum rT3 was
associated with all-cause mortality in the fully adjusted
model: that is independent of prevalent disease burden. In
contrast, lower FT3 was also associated with both all-
cause and cardiovascular mortality but following full cor-
rection for disease burden, these associations were lost.
These findings broadly confirm those of previous studied
cohorts of older people (2, 29), and are in line with the
known pathophysiological mechanisms whereby low FT3
andhigher rT3 are nonspecifically associatedwith increas-
ing ill health and disease burden (44, 45). Interestingly,
our analysis is one of only a few to look at serum rT3 in
individuals of this age, and our data suggest that high rT3
is a stronger predictor of all-causemortality than lowFT3,
independent of disease burden. This finding is consistent
with a longitudinal study of 403 Dutch males age 73–94
years inwhichagroupwithhigher rT3butnormal FT3had
better performance status than those with lower FT3 (43).
One explanation may be that rT3 is more sensitive to the
Table 2. Relationship Between Thyroid Hormones and All-cause and Cardiovascular Mortality in the Full Cohort
and in Euthyroid Participants; HRs (per Unit Increase) and 95% CIs
Model 1a Model 2b
HRc 95% CI P-Value HRc 95% CI P-Value
Full cohort (n  643)
All-cause mortality
TSH 0.92 0.78–1.09 .32 0.87 0.71–1.07 .19
FT3 0.81 0.73–0.91 .001 0.91 0.81–1.01 .08
FT4 1.09 0.99–1.21 .08 1.07 0.96–1.19 .22
rT3 1.23 1.12–1.34 .001 1.18 1.07–1.31 .001
Cardiovascular mortality
TSH 1.03 0.88–1.19 .74 0.96 0.74–1.25 .76
FT3 0.85 0.74–0.97 .02 0.97 0.84–1.12 .70
FT4 1.03 0.90–1.17 .71 0.99 0.86–1.15 .93
rT3 1.22 1.08–1.38 .002 1.13 0.99–1.29 .07
Euthyroid at baseline (n  534)
All-cause mortality
TSH 0.64 0.43–0.95 .027 0.72 0.47–1.09 .12
FT3 0.75 0.66–0.84 .001 0.84 0.74–0.96 .008
FT4 1.05 0.94–1.18 .40 1.03 0.90–1.17 .69
rT3 1.22 1.11–1.35 .001 1.17 1.05–1.31 .006
Cardiovascular mortality
TSH 0.74 0.44–1.24 .26 0.88 0.51–1.52 .65
FT3 0.78 0.66–0.91 .002 0.90 0.77–1.06 .22
FT4 1.00 0.86–1.17 .98 0.96 0.81–1.13 .61
rT3 1.21 1.06–1.38 .006 1.10 0.95–1.28 .20
a Adjusted for age and sex
b Adjusted for age, sex, education, BMI, smoking, disease count
c HR per SD increase of: 3.223 mU/L TSH, 0.496 pmol/L FT3, 2.470 pmol/L FT4, 0.109 nmol/L rT3.
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presence of preclinicalmorbidities (eg, early tissue inflam-
mation or covert cancer); the alternative being that our
disease count incorporating 17 common conditions is in-
complete and that serum rT3 is sensitive to uncounted
conditions not included in the adjustment. Our deeper
examination of the relationship between thyroid hor-
mones and mortality by fitting cubic splines showed that
most of the hormones were linearly related to mortality.
The exception was FT3 where both low and high values
were predictive of mortality in the very old.
Disabilities
Scant data exist about the relationship between thyroid
function, functional status, and future disability in this age
group (43, 46, 47). Our analysis showed that baseline
serum TSH, FT3, and rT3 each predicted future disability
with the strongest effects seen in women. However, given
that these associations are attenuated following adjust-
ment bybaseline disease count andBMI, these factorsmay
be on the causal pathway between thyroid function and
disability. The association of disability with lower TSH in
Figure 2. Restricted cubic spline curves of dose-response relationship between TSH, FT3, FT4, rT3, and all-cause mortality, adjusted for age, sex,
education, smoking status, BMI, and disease count, in the Newcastle 85 Study.
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men isparticularly interestinggiven that, in cohort studies,
subclinical hyperthyroidism or lower serum TSH have
been associated with many involutional disease states in-
cluding dementia, osteoporosis, AF, muscle weakness,
low bone density, and fracture (12–14, 18, 20, 48, 49). It
has widely been assumed that these associations are
caused by subclinical hyperthyroidism with detrimental
effects of excess thyroid hormone, for instance its proar-
rhythmic effect on the heart leading to AF, despite the fact
that serum thyroid hormones are within reference range
(1, 13–15, 29, 41, 42).Our findings that lower serumTSH
predicts future disability, even when adjusted for baseline
disease count, suggests that in advanced old age, lower
TSH (and in the unadjusted analysis, lower FT3/higher
rT3) correlates with an increasing burden of nonthyroidal
disease. This is consistent with the Health ABC study,
showing that in a cohort with a mean age of 75 years, the
groupwith higher serumTSH (4.5–6.99mU/L) had faster
gait speed and better cardiorespiratory fitness than those
with lower TSH (46).
Limitations
Our prospective observational study has some limita-
tions. A relatively low number of individuals were studied
and so with lower numbers of vascular events, there was
less power to detect a significant difference in cardiovas-
cular deaths, compared with all-cause mortality. How-
ever, this is still the largest study of this kind in this age
group, as far as we are aware. In addition, we assessed 17
common comorbid conditions for which we adjusted in
our multivariate analyses. It is possible that there may be
other less common yet influential conditions that have not
been taken into account. Furthermore, similar to most
other longitudinal observational cohort studies, theremay
be a bias toward healthier people participating. In partic-
ular, it seems probable that individuals with sensory im-
pairmentsmay have been under-represented in the cohort.
Nevertheless, in contrast with most studies of this age
group, we did include participants with advanced frailty
living in supervised care and nursing homes as well as
those with dementia, so our results should be representa-
tive for age-matched populations. Thus, these self-evident
potential limitations, aswell as other unknown confound-
ers, may also have influenced the results of our study.
Summary
In a cohort of 85-year-olds, baseline serum rT3 was
associated with all-cause mortality during a 9-year period
of followup, and may be a more sensitive marker for non-
thyroidal illness than FT3. No significant mortality asso-
ciations were found with serum TSH, FT3, or FT4. How-
ever, in men lower serum TSH, and in women higher rT3
predicted disability. Although it is well established that
low FT3 is associated with nonthyroidal illness, our find-
ings are consistent with reduced serum TSH also being a
marker for disability in older age. These data suggest that
there is little detriment associated with subclinical hypo-
thyroidism in this age group.
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